Delisting risk
VivoSim Labs (VIVS)
Preclinical liver and intestinal toxicology testing with primary human tissue models.
$0.2800
Pre-market+0.00 (+0.07%)
At close$0.2798(+0.39%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions23 holders · as of Mar 31, 2026 | 0.66% | 97.9K shares | |
| Insiders6 holders · as of Sep 1, 2026 | 0.75% | 111.6K shares | |
| Otherremainder | 98.59% | 14.64M shares |
14.85M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (14.85M in the company's Sep 3, 2026 report, 2.57M elsewhere); stakes use the report.
Institutions13F, as of Mar 31, 2026
23 holders · 97.9K shares · 5 new positions · 9 increased · 2 reduced · 8 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Geode Capital Management, LLC | 36.9K | 0.25% | +16.2K | May 15, 2026 |
| Goldman Sachs Group Inc | 16.1K | 0.11% | +16.1Knew | May 15, 2026 |
| Vanguard Capital Management LLC | 15.4K | 0.10% | +15.4Knew | May 15, 2026 |
| BlackRock, Inc. | 11.8K | 0.08% | 0 | May 13, 2026 |
| Vanguard Fiduciary Trust Co | 7.0K | 0.05% | +7.0Knew | May 8, 2026 |
| Citigroup Inc | 6.5K | 0.04% | +1.6K | May 11, 2026 |
| Tower Research Capital LLC (TRC) | 2.3K | 0.02% | +420 | May 15, 2026 |
| UBS Group AG | 952 | 0.01% | +936 | May 5, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 31, 2026 | Tony Serge Lialinofficer: Chief Commercial Officer | Purchase | 10,000 | $0.2804 | 10,000 |
| Nov 17, 2025 | David Gobeldirector | Sale | 3,266 | $2.24 | 0 |
CongressHouse and Senate disclosures
Not reported.